Crestor Patent Battle Could Have Ripple Effect: Is A Salt Equivalent To Base Compound?
Executive Summary
Watson filed a 505(b)(2) NDA for a zinc salt of AstraZeneca’s Crestor, which AstraZeneca claims infringes its patent; if Watson prevails more generic manufacturers may pursue this pathway around a patent.
You may also be interested in...
Deals Of The Week: Pfizer Management Updates Thoughts On Split
Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.
Crestor Patent Settlement Allows Actavis Generic Entry In May 2016
The agreement permits Actavis to launch its generic version of AstraZeneca’s Crestor 67 days before the patent on the cholesterol-lowering drug expires in return for paying AstraZeneca 39% of its net sales during this period; Actavis may also launch its alternative zinc salt formulation of Crestor at the same time.
Pfizer Norvasc Patent Term Extension Keeps AmVaz Off The Market Until 2007
Pfizer's Norvasc (amlodipine besylate) will not face competition from Dr. Reddy's calcium channel blocker AmVaz until 2007 under a federal appeals court ruling